NCT03319290
Unknown
N/A
Medical Provider Experience Assessment Healthcare Decisions Post-Testing, Risk Reducing, and Preventative Strategies Using BRCA2 and BRCA2 Genetic Testing
Data Collection Analysis Business Management1 site in 1 country2,000 target enrollmentOctober 17, 2017
ConditionsHereditary Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hereditary Cancer
- Sponsor
- Data Collection Analysis Business Management
- Enrollment
- 2000
- Locations
- 1
- Primary Endpoint
- Provider Structures and Processes
- Last Updated
- 7 years ago
Overview
Brief Summary
Observational study is to increase surveillance for breast and ovarian cancers, also to determine targeted risk-reducing and preventative strategies.
Detailed Description
The general design of this study is collecting data and reviewing the Principal Investigators' (P.I.) Standard Operating Procedures (SOP) on BRCA testing and changes made to their specific SOP.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must be a Medical Practitioner
- •Medical Doctor (MD)
- •Doctor of Osteopathic (DO)
- •Physician Assistant (PA)
- •Advanced Practice Registered Nurse (APRN)
- •Nurse Practitioner (NP)
- •Must have a current standard operating procedure that includes obtaining/reviewing medical history and family medical history
Exclusion Criteria
- •Government-funded insurance data cannot be included in the study.
Outcomes
Primary Outcomes
Provider Structures and Processes
Time Frame: 36 months
Plan of Care Changes due to BRCA testing. Provider based observational survey system on the health and well-being of patients and populations
Study Sites (1)
Loading locations...
Similar Trials
Completed
N/A
Improving Adherence to Recommended Surveillance in Breast Cancer SurvivorsBreast CancerNCT02189278Duke University100
Unknown
N/A
Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial CancerOvarian NeoplasmsNCT02524808Fundación de investigación HM230
Completed
Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.Breast CancerProstate CancerOvarian CancerNCT03840200Hoffmann-La Roche51
Completed
N/A
Observational Study to Develop Dosing ChartInfertile Women Undergoing IVF or ICSINCT04227171LG Chem534
Unknown
N/A
Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation TestingBreast CancerBRCA1 MutationBRCA2 MutationRecurrent Breast CancerMetachronous NeoplasmNCT03475979Seoul National University Hospital1,564